

Shannon Puhalla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11164362/publications.pdf>

Version: 2024-02-01

48
papers

685
citations

623734

14
h-index

580821

25
g-index

48
all docs

48
docs citations

48
times ranked

1299
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 721-735.	2.3	5
2	Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 643-654.	2.3	1
3	Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110596.	3.2	9
4	TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 22.	5.0	10
5	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1289-1301.	2.3	29
6	Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer. <i>BMC Cancer</i> , 2019, 19, 578.	2.6	4
7	Targeted mutation detection in breast cancer using MammaSeq. <i>Breast Cancer Research</i> , 2019, 21, 22.	5.0	28
8	Parental Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA1/2-Mutated Cancer or PARP-Sensitive Tumor Types. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 977-987.	2.0	17
9	Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. <i>Breast Journal</i> , 2017, 23, 718-722.	1.0	16
10	Phase I study of veliparib in combination with gemcitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 631-643.	2.3	11
11	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. <i>Future Oncology</i> , 2017, 13, 307-320.	2.4	41
12	TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). <i>Journal of Clinical Oncology</i> , 2017, 35, 1005-1005.	1.6	32
13	LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM). <i>Journal of Clinical Oncology</i> , 2017, 35, 1011-1011.	1.6	3
14	LCCC 1525: Combination immunotherapy with cyclophosphamide plus pembrolizumab in patients with advanced triple negative breast cancer (TNBC). <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1125-TPS1125.	1.6	0
15	Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173). <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1127-TPS1127.	1.6	0
16	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study. <i>Breast Cancer: Targets and Therapy</i> , 2016, Volume 8, 231-239.	1.8	2
17	ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2004-2004.	1.6	16
18	HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?. <i>Journal of Clinical Oncology</i> , 2016, 34, 612-612.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Palbociclib's effect on estrogen receptor mutations in metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 533-533.	1.6	2
20	Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy.. Journal of Clinical Oncology, 2016, 34, e23265-e23265.	1.6	1
21	Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease?. Journal of Clinical Oncology, 2016, 34, 580-580.	1.6	0
22	Utilization of Magee equation 3 in ER-positive, HER2-negative/equivocal tumors to determine pathologic response to neoadjuvant therapy.. Journal of Clinical Oncology, 2016, 34, 11594-11594.	1.6	0
23	Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. SpringerPlus, 2015, 4, 532.	1.2	12
24	Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro-Oncology, 2015, 17, 639-651.	1.2	62
25	A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1015-1015.	1.6	38
26	Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 170-170.	1.6	13
27	Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2015, 33, 554-554.	1.6	0
28	Yield of adequate tissue on research biopsies with pathologic review.. Journal of Clinical Oncology, 2015, 33, e17626-e17626.	1.6	0
29	Next-generation sequencing in a cohort of metastatic breast cancer (MBC) patients.. Journal of Clinical Oncology, 2015, 33, e22053-e22053.	1.6	0
30	Should We Embrace or Ablate Our Urge to (Ovarian) Suppress?. Journal of Clinical Oncology, 2014, 32, 3920-3922.	1.6	5
31	BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Frontiers in Oncology, 2014, 4, 19.	2.8	36
32	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Research and Treatment, 2014, 146, 557-566.	2.5	59
33	A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Investigational New Drugs, 2014, 32, 1285-1294.	2.6	16
34	Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer. Clinical Breast Cancer, 2014, 14, 405-412.	2.4	55
35	Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).. Journal of Clinical Oncology, 2014, 32, 2570-2570.	1.6	49
36	Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG).. Journal of Clinical Oncology, 2014, 32, 2572-2572.	1.6	2

#	ARTICLE	IF	CITATIONS
37	TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).. Journal of Clinical Oncology, 2014, 32, 528-528.	1.6	4
38	Effect of tumor subtype on overall survival in brain metastatic breast cancer patients treated with cranial irradiation.. Journal of Clinical Oncology, 2014, 32, 74-74.	1.6	0
39	Treatment of HER2-positive breast cancer: looking backwards briefly. Lancet Oncology, The, 2013, 14, 1250-1251.	10.7	4
40	TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).. Journal of Clinical Oncology, 2013, 31, 515-515.	1.6	2
41	TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer.. Journal of Clinical Oncology, 2013, 31, 527-527.	1.6	1
42	Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. Molecular Oncology, 2012, 6, 222-236.	4.6	63
43	Hematopoietic growth factors: Personalization of risks and benefits. Molecular Oncology, 2012, 6, 237-241.	4.6	16
44	Single institution experience with neoadjuvant chemotherapy for metaplastic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, 1038-1038.	1.6	1
45	A phase II study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.. Journal of Clinical Oncology, 2012, 30, 3049-3049.	1.6	11
46	Adjuvant Endocrine Therapy for Breast Cancer: Don't Ditch the Switch!. Journal of the National Cancer Institute, 2011, 103, 1280-1282.	6.3	5
47	PARP inhibitors: what we know and what we have yet to know. Oncology, 2010, 24, 62, 65-6.	0.5	1
48	Bevacizumab in breast cancer: the best is yet to come?. Oncology, 2009, 23, 332, 335.	0.5	0